

Lys¹⁸-GLP-1(7-37) [SEQ ID NO:14], Gly⁸-GLP-1(7-36)NH₂ [SEQ ID NO:15], Gly⁸-GLP-1(7-37)OH [SEQ ID NO: 16], Val⁸-GLP-1(7-37)OH [SEQ ID NO:5], Met⁸-GLP-1(7-37)OH [SEQ ID NO:18], acetyl-Lys⁹-GLP-1(7-37) [SEQ ID NO:19], Thr⁹-GLP-1(7-37) [SEQ ID NO:20], d-Thr⁹-GLP-1(7-37) [SEQ ID NO:21], Asn⁹-GLP-1(7-37) [SEQ ID NO:22], d-Asn⁹-GLP-1(7-37) [SEQ ID NO:23], Ser²²-Arg²³-Arg²⁴-Gln²⁶-GLP-1(7-37) [SEQ ID NO:24], Arg²³-GLP-1(7-37) [SEQ ID NO:25], Arg²⁴-GLP-1(7-37) [SEQ ID NO:26], α -methyl-Ala⁸-GLP-1(7-36)NH₂ [SEQ ID NO:27], and Gly⁸-Gln²¹-GLP-1(7-37)OH [SEQ ID NO:28], and the like.

In the Claims


(marked-up claims provided as Attachment B)

In response to the Examiner's earlier restriction requirement in the parent case, Claims 26-32, 44, and 45 were canceled. Thus, only Claims 33-43 and 46 are pending.

Claim 42 has not been amended, but is included below for the Examiner's convenience.

Applicants request the following claim amendments and new claims be entered:

Delete Claims 41, 43, and 46.

 33 (amended) ~~Flat red shaped or plate-like crystals of a~~
peptide having the amino acid sequence of SEQ ID NO:5
prepared by crystallizing the peptide from an aqueous
solution comprising the peptide and between about 2-15%
(v/v) ethanol or [between about 2-15% (v/v)] propanol, and
wherein the solution optionally comprises ammonium sulfate
or zinc and provided that the crystals vary in size from
between about 2-25 microns by 10-150 microns with a depth
from ^{about} 0.5-5 microns a

34. (amended) The crystals of Claim 33 wherein the concentration of the peptide in the solution is between about 1-10 mg/ml and the pH of the solution is between about 6 and 7.

35. (amended) The crystals of Claim 34 wherein the concentration of peptide in the solution is between about 2-7 mg/ml and the solution comprises between about 3-13% ethanol (v/v).

36. (amended) The crystals of Claim 35 wherein the solution comprises ammonium sulfate at a concentration of about 1% (w/v).

37. (amended) The crystals of Claim 33 wherein the Concentration of peptide in the solution is between about 1-20 mg/mL, the molar ratio of zinc to peptide is between about 0.5 to 1.7, and the pH of the solution is between about 7-10.

38. (amended) The crystals of Claim 37 wherein the concentration of peptide in the solution is between about 2-10 mg/mL, the molar ratio of zinc to peptide is between about 0.6 to 1.5, and the pH of the solution is between about 7.2-9.7.

39. (amended) Flat rod shaped or plate-like crystals of a peptide having the amino acid sequence of SEQ ID NO:5 prepared by crystallizing the peptide from an aqueous solution comprising the peptide and between about 2-15% (w/v) of a mono or disaccharide selected from trehalose, mannitol, glucose, erythrose, ribose, galactose, fructose, maltose, sucrose or lactose; and wherein the solution optionally comprises ammonium sulfate or zinc and provided that the crystals vary in size from between about 2-25